Internal Medicine Department, Saint Elizabeth Health Center, 1044 Belmont Ave, Youngstown, OH 44501, USA.
Curr Oncol Rep. 2013 Aug;15(4):424-32. doi: 10.1007/s11912-013-0330-8.
Concurrent chemotherapy and radiation therapy remains the standard-of-care treatment in patients with unresectable stage III non-small-cell lung cancer. Most regimens include low doses of radiosensitizing agents. Because of concern for the presence of micrometastatic disease and the high rate of systemic failure, many trials have addressed the role of additional consolidation chemotherapy. Only a few of these studies have been performed in a randomized setting on a large number of patients, and the rest are smaller phase I and phase II trials that explore the safety and efficacy of different chemotherapy regimens. More recently, targeted agents have also been evaluated in such regimens, although molecular and histologic markers have not been fully incorporated in these studies. In this review, we discuss these trials and compare the different sequences and regimens of systemic doses of chemotherapy when delivered in addition to concurrent chemotherapy and radiation therapy.
同期放化疗仍然是不可切除的 III 期非小细胞肺癌患者的标准治疗方法。大多数方案包括低剂量的放射增敏剂。由于担心存在微转移疾病和高全身失败率，许多试验已经探讨了额外巩固化疗的作用。只有少数这些研究在大量患者中以随机的方式进行，其余的是较小的 I 期和 II 期试验，探索不同化疗方案的安全性和有效性。最近，靶向药物也已在这些方案中进行了评估，尽管分子和组织学标志物尚未完全纳入这些研究。在这篇综述中，我们讨论了这些试验，并比较了同期放化疗中附加全身剂量化疗的不同序列和方案。
